Search

Search Constraints

You searched for: Author/Creator Huang, Huiqiang

Search Results

1. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study*. Issue 1 (2nd January 2019)

2. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. Issue 1 (2nd January 2019)

3. Association of circulating tumor DNA from the cerebrospinal fluid with high‐risk CNS involvement in patients with diffuse large B‐cell lymphoma. Issue 1 (15th January 2021)

4. Bendamustine in the treatment of patients with indolent non‐Hodgkin lymphoma refractory or relapse to rituximab treatment: An open‐label, single‐agent, multicenter study in China. Issue 4 (21st December 2022)

5. Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T‐cell lymphoma in children and adolescents. Issue 5 (23rd January 2021)

6. Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma. (December 2021)

7. CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma. (28th November 2021)

8. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study. Issue 4 (3rd April 2018)

9. High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL). Issue 1 (2nd January 2021)

10. Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial. Issue 4 (30th August 2022)